D-Loperamide as a Marker of PgP Function in Gliomas

D-洛哌丁胺作为胶质瘤 PgP 功能的标志物

• 批准号: 8349499
• 负责人: Teri Kreisl
• 金额: $ 38.02万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349499
• 关键词: ABCB1 gene; Archives; Biological Assay; Blood - brain barrier anatomy; Brain Neoplasms; Cerebrovascular Circulation; Correlative Study; Data Correlations; Eligibility Determination; Endothelium; Genetic Polymorphism; Genomics; Glioma; Image; Loperamide; Magnetic Resonance Imaging; Measures; Methods; Molecular; Outcome; P-Glycoprotein; Patients; Perfusion; Pilot Projects; Positron-Emission Tomography; Regulation; Scanning; Tumor Tissue; case history; chemotherapy; design; electric impedance; fluorodeoxyglucose positron emission tomography; in vivo; interest; molecular marker; neurotoxicity; radioligand; response; tumor; uptake

Objectives: Primary 1. To measure the uptake of [11C]N-desmethyl-loperamide ([11C]dLop) using PET imaging as a marker of P-glycoprotein function in patients with intracranial gliomas Secondary 1. Correlate [11C]dLop PET uptake with perfusion MRI parameters and FDG PET uptake for volumes of interest (VOI) determined by the baseline MRI. 2. Develop exploratory data for the correlation of [11C]dLop PET imaging with patient outcomes such as response to therapy, survival, and neurotoxicity 3. Develop exploratory data for the correlation of [11C]dLop PET imaging with immunohistochemical and molecular genomic assays of MDR1 and Pgp Eligibility: Patients with predominantly non-enhancing intracranial gliomas will be eligible. Design: This is a pilot study of [11C]dLop PET imaging in 10 patients with intracranial glioma. Standard uptake values (SUVs) corrected for cerebral blood flow determined by [15O]H20 PET scans will be correlated to DCE-MRI (obtained within prior 2 weeks) and FDG-PET (obtained within 4 weeks) to characterize locoregional differences in Pgp function. When available, correlative studies performed on archived tumor tissue acquired immediately subsequent to [11C]dLop scanning will include immunohistochemical assays of Pgp expression, as well as characterization of MDR1 polymorphisms. Patient case histories will be followed longitudinally to make observations about how [11C]dLop imaging may correlate with patient outcomes such as response to therapy, survival, and neurotoxicity.

Objectives: Primary 1. To measure the uptake of [11C]N-desmethyl-loperamide ([11C]dLop) using PET imaging as a marker of P-glycoprotein function in patients with intracranial gliomas Secondary 1. Correlate [11C]dLop PET uptake with perfusion MRI parameters and FDG PET uptake for volumes of interest (VOI) determined by the baseline MRI. 2。开发探索性数据，以[11C] DLOP PET成像与患者的结果（例如对治疗，生存和神经毒性的反应，生存和神经毒性）3。开发探索性数据，以相关[11C] DLOP PET与免疫组织化学和分子基因组及时的占主导地位的患者： 有资格的。设计：这是对10例颅内胶质瘤患者的[11C] DLOP PET成像的试点研究。根据[15O] H20 PET扫描确定的脑血流校正的标准吸收值（SUV）将与DCE-MRI（在前2周内获得）和FDG-PET（在4周内获得），以表征PGP功能的局部区域差异。如果有的话，对[11C] DLOP扫描后立即获得的存档肿瘤组织进行的相关研究将包括PGP表达的免疫组织化学测定，以及MDR1多态性的表征。将纵向遵循患者病例的历史，以观察[11C] DLOP成像与患者结果（例如对治疗，生存和神经毒性的反应）的相关性。